Extreme suicidality following serotonin syndrome.
D000293:Adolescent; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002997:Clomipramine / Q000008:administration & dosage / Q000009:adverse effects; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004308:Dothiepin / Q000008:administration & dosage / Q000009:adverse effects*; D004334:Drug Administration Schedule; D004565:Electroconvulsive Therapy; D005260:Female; D006801:Humans; D008094:Lithium / Q000008:administration & dosage / Q000009:adverse effects*; D010624:Phenelzine / Q000008:administration & dosage / Q000009:adverse effects*; D011985:Receptors, Serotonin / Q000187:drug effects*; D012008:Recurrence; D016728:Self-Injurious Behavior / Q000139:chemically induced / Q000523:psychology; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control / Q000523:psychology*; D013405:Suicide / Q000523:psychology*; D013577:Syndrome; D000092864:Suicide Prevention
D000928:Antidepressive Agents; D011985:Receptors, Serotonin; D008094:Lithium; D002997:Clomipramine; D010624:Phenelzine; D004308:Dothiepin